



Source details

Annals of Medicine and Surgery

Scopus coverage years: from 2012 to Present

Publisher: Elsevier

E-ISSN: 2049-0801

Subject area: Medicine: Surgery

Source type: Journal

CiteScore 2021

1.4



SJR 2021

0.373



SNIP 2021

0.965



[View all documents >](#)

[Set document alert](#)

[Save to source list](#) [Source Homepage](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

i Improved CiteScore methodology



CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021 ▼

$$1.4 = \frac{2,710 \text{ Citations 2018 - 2021}}{1,918 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022 ⓘ


$$1.4 = \frac{4,237 \text{ Citations to date}}{3,082 \text{ Documents to date}}$$

Last updated on 05 October, 2022 • Updated monthly

CiteScore rank 2021 ⓘ

Category	Rank	Percentile
Medicine		
Surgery	#266/469	43rd

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)



[i](#) [x](#)

Limited-Time Only To Go Coco

Give your day a Boost of Coco and go Loco today with our new Coconut Smoothies. Order now!

Boost Juice Indonesia

Learn More

Annals of Medicine and Surgery

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
Netherlands 	Medicine Medicine (miscellaneous) Surgery	Elsevier BV	30
PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	20490801	2012-2021	Homepage How to publish in this journal annalsjournal@elsevier.com

SCOPE






Annals of Medicine and Surgery is an online-only, peer-reviewed open access journal with a global outlook and focus on those training in medicine and surgery (postgraduate and undergraduate). AMS contains a mix of original clinical and basic science research, reviews, editorials, commentary, perspectives, debate, opinion, case reports and journal club reports. The journal crosses the whole disease spectrum of medicine and surgery but does also have a special focus on the following areas: -Patient safety- Human factors, teamwork, communication and professionalism- Quality improvement science and practice- Evidence based medicine- Implementation science – clinical evidence into practice- Leadership and management- Medical education, teaching, and training- Public and global health- Healthcare policy, delivery, commissioning, and resource management- Use of technology and health informatics- Clinical ethics and medical law- Research and innovation – bedside to bench and back again – including applications like personalised medicine.






Join the conversation about this journal

Quartiles

FIND SIMILAR JOURNALS

<p>1 International Journal of Surgery NLD</p> <p>80% similarity</p>	<p>2 International Journal of Surgery Open GBR</p> <p>73% similarity</p>	<p>3 International Journal of Surgery Case Reports NLD</p> <p>67% similarity</p>	<p>4 BMC Surgery GBR</p> <p>61% similarity</p>
---	--	--	--





Annals of Medicine and Surgery
Q3
Medicine (miscellaneous)
Best quartile
SJR 2021
0.37
powered by scimagojr.com

← Show this widget in your own website

Just copy the code below and paste within your html code:

<a href="https://www.scimagojr.com/..."

SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization tool**.



Metrics based on Scopus® data as of April 2022

K Khalid 10 months ago

Would you inform me what is the impact factor of this journal please?

reply

SCImago Team

**Melanie Ortiz** 9 months ago

Dear Khalid, thank you very much for your comment. SCImago Journal and Country Rank uses Scopus data, our impact indicator is the SJR (Check it on our website). We suggest you consult the Journal Citation Report for other indicators (like Impact Factor) with a Web of Science data source. Best Regards, SCImago Team

S Sultan jarrar 2 years ago

Dear SCIMAGO team,

Could you please tell me if this journal considered to be q2 or q3 ? There is a little confusion about it .

Kind regards

reply

**Melanie Ortiz** 2 years ago

SCImago Team

Dear Sultan,

thank you for contacting us. For every journal, the annual value of the SJR is integrated into the distribution of SJR values of all the subject categories to which the journal belongs. There are more than 300 subject categories. The position of each journal is different in any category and depends on the performance of the category, in general, and the journal, in particular .

Best Regards, SCImago Team

A Anton 2 years ago

Dear sir/ madam, please tell if the journal status Q2 or Q3?

reply

**Melanie Ortiz** 2 years ago

SCImago Team

Dear Anton, thank you for contacting us. For every journal, the annual value of the SJR is integrated into the distribution of SJR values of all the thematic categories to which the journal belongs. There are more than 300 thematic categories. The position of each journal is different in any category and depends on the performance of the category, in general, and the journal, in particular. The next SJCR's update will be made throughout June 2020. Best Regards, SCImago Team

S **Saad** 2 years ago

Dear. Melanie
Thank you very much for your reply.
Best regards.
Saad

reply



Melanie Ortiz 2 years ago

SCImago Team

Dear Saad, thanks for your participation! Best Regards, SCImago Team

S **Saad** 3 years ago

Dear.
I want ask about annals of medicine and surgery journal. Is it Q2 or Q3 according to 2019.
Thank you.
Best regards.

reply



Melanie Ortiz 3 years ago

SCImago Team

Dear Saad,
Thank you for contacting us. Our data come from Scopus, they annually send us an update of the data. This update is send to us around April / May every year. Thus, the indicators for 2019 will be available in June 2020 and before that we can't know what will happen with this journal. Best Regards, SCImago Team

Leave a comment

Name

Email

(will not be published)

I'm not a robot reCAPTCHA
[Privacy](#) - [Terms](#)

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2022. Data Source: Scopus®



[Edit Cookie Consent](#)



ISSN: 2049-0821

ANNALS OF MEDICINE & SURGERY



EDITIO • DILIGENTIA • FIDES

www.annalsjournal.com

ScienceDirect



ScienceDirect®

Submit your article

Menu



Search in this journal

Volume 71

November 2021

[< Previous vol/issue](#)

[Next vol/issue >](#)

Receive an update when the latest issues in this journal are published

[Sign in to set up alerts](#)

Open access

Editorial Board

Article 103066

[Download PDF](#)

Original Research

FEEDBACK

[Submit your article](#)

Menu



Search in this journal

[Download PDF](#) [Article preview](#) Research article *Open access*

Osteocalcin biomarker level evaluation on fracture healing with bone defect after stromal vascular fraction application in murine model

Respati S. Dradjat, Panji Sananta, Rizqi Daniar Rosandi, Lasa Dhakka Siahaan

Article 103020

[Download PDF](#) [Article preview](#) Research article *Open access*

Association between serum PGE₂ levels and degree of acid-fast bacilli positivity in sputum of pulmonary tuberculosis patients

Herley Windo Setiawan, Resti Yudhawati, Irmu Syafaah

Article 103008

[Download PDF](#) [Article preview](#) Research article *Open access*

A safe, reliable, and efficient robot-assisted port site closure for robot-assisted gastrectomy

Noriyuki Hirahara, Takeshi Matsubara, Shunsuke Kaji, Yuki Uchida, ... Yoshitsugu Tajima

Article 103001

[Download PDF](#) [Article preview](#) Research article *Open access*

The relative citation ratio and the h-index among academic ophthalmologists: A retrospective cross-sectional analysis

FEEDBACK

Annals of Medicine and Surgery

Open access

Submit your article

Menu

Search in this journal

Page 1 of 2

Previous vol/issue

Next vol/issue

ISSN: 2049-0801

Copyright © 2022 IJS Publishing Group Ltd. All rights reserved



Copyright © 2022 Elsevier B.V. or its licensors or contributors.
ScienceDirect® is a registered trademark of Elsevier B.V.



FEEDBACK



Annals of Medicine and Surgery

Editorial Board

Editor-in-Chief

Riaz Agha, London, England, UK

Assistant Managing and Executive Editor

Maliha Agha, London, England, UK

Assistant Editors

Adam Frampton, London, England, UK
Jorg Kleef, Munich, Germany
Deepthi Mani, Washington, USA
David Rosin, Bridgetown, Barbados
Peter Schemmer, Heidelberg, Germany

Social Media Editor

Riaz Agha, London, UK

Managing Editor

Alexander James Fowler, London, England, UK

Statistical Editor

Lai-Chu See, Taoyuan, Taiwan

Associate Staff Editors

Sergio Acuna, Toronto, Canada
Guido Alsfasser, Rostock, Germany
Fernando Angarita, Toronto, Canada
James Clark, Plymouth, England, UK
Terry Evans, London, England, UK
Shivani Garg, Wisconsin, USA
Todd Golden, Arizona, USA
Fermin Guerrero Del Angel, Madero, Mexico
Eleni Ntouvali, Athens, Greece

Assistant Commissioning Editors

Ahmed Al-Jabir, London, UK
Zaid Alsafi, London, UK
Thomas Franchi, Sheffield, UK
Christos Iosifides, London, UK
Ahmed Kerwan, London, UK

Mehdi Khan, London, UK
Ginimol Mathew, London, UK
Maria Nicola, London, UK
Niamh O'Neill, London, UK
Catrin Sohrabi, London, UK

Junior Staff Editors

Sumita Agrawal, Jodhpur, India
Bakir Al-Dulaimy, London, UK
Mohammed Anwar, London, UK
Martinique Vella Baldacchino, Glasgow, UK
Maria Borrelli, London, UK
Kerry Anne Burke, Manchester, England, UK
Adam Cristaudo, Cairns, Australia
Buket Gundogan, London, UK
Adam Gwozdz, London, England, UK

Mike Hu, California, USA
Tobin Joseph, London, UK
Kiron Koshy, London, UK
Seon-Young Lee, Southampton, England, UK
Chris Limb, London, England, UK
Yasser Al Omran, London, England, UK
Karishma Shah, Oxford, UK
Rachel Thavayogan, London, UK

Executive Committee

Sir Graeme Catto, Aberdeen, Scotland, UK
Sir Barry Jackson, London, England, UK

David Rosin, Bridgetown, Barbados

Editorial Board

Xiao-Ping Chen, Wuhan, China
Marc Cohen, Victoria, Australia
David Green, London, England, UK
Saeed Sadiq Hamid, Karachi, Pakistan
Peter Hutchinson, Cambridge, England, UK
Peter Littlejohns, London, England, UK
Ashok Mahapatra, New Delhi, India
Judy McKimm, Swansea, Wales, UK
Dattatraya Muzumdar, Mumbai, India

Ashish Nabar, Mumbai, India
Fabio Nicoli, London, UK
John Norcini, Philadelphia, PA, USA
Christoph Paasch, Berlin, Germany
Daniel Sokol, London, England, UK
Jamsheer Talati, Karachi, Pakistan
John V. Thomas, Birmingham, AL, USA
Tim Gabe Williams, Kent, England, UK
Zhao-Fan Xia, Shanghai, China

Elsevier

Executive Publisher

Allan Ross, New York, USA

Administrative Editor

Joanne Frankland, Oxford, UK

Marketing Manager

Wendy Montalvo, New York, USA

Journal Manager

Tamsyn Hopkins, Exeter, UK

Senior Business Development

Executive (Reprints)

Emma Steel, London, UK

Advertising Sales Manager

Robert Bayliss, London, UK

Account Manager (Supplements)

Evelina Euren, The Netherlands



Cross-sectional Study

Association between serum PGE₂ levels and degree of acid-fast bacilli positivity in sputum of pulmonary tuberculosis patients

Herley Windo Setiawan^{a,b}, Resti Yudhawati^{a,*}, Irmu Syafaah^a^a Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, Indonesia^b Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga – Universitas Airlangga Teaching Hospital, Surabaya, Indonesia

ARTICLE INFO

Keywords:

Positivity of acid-fast bacilli
Pulmonary tuberculosis
Serum PGE₂ levels

ABSTRACT

Background: *Mycobacterium tuberculosis* that infected apoptotic macrophages is triggered by PGE₂. Apoptosis suppresses the growth of *Mycobacterium tuberculosis* bacteria, which is shown in the results of acid-fast bacilli (AFB) in the sputum that becomes a marker of the number of bacteria.

Objective: Analyzing the association between serum PGE₂ levels and the positivity of AFB in the sputum of tuberculosis patients.

Methods: A cross-sectional study was carried out from August 2019–July 2020. Serum PGE₂ levels and AFB levels in sputum were collected from participants. Data analysis used the Chi-square test and Spearman's correlation with $p < 0.05$.

Results: The average participants' serum PGE₂ levels were 446.37 ± 510.27 pg/ml, with a median value of 216.95 pg/ml. Most participants had normal serum PGE₂ levels (62.9%). Most participants had a high positivity of AFB in sputum (58.1%). Analysis of the association between serum PGE₂ levels and the degree of AFB positivity in sputum obtained $r = -0.036$ and p -value = 0.780.

Conclusion: There is a weak negative association between serum PGE₂ levels and the degree of AFB positivity in sputum but not statistically significant.

1. Introduction

Tuberculosis (TB) is still a global health problem [1]. The increase in TB cases is accompanied by an increase in drug-resistant TB (DR TB) cases. In the Global Tuberculosis Report, WHO reported that 10 million people were suffering from TB, both new and relapsed cases, with 558,000 of whom had DR TB [2]. Indonesia ranks third in the country with the highest TB incidence globally, both new and relapse cases. The number of new and relapsed TB cases in Indonesia in 2017 was 442,172, and 54% of them were confirmed bacteriologically by either acid-fast bacilli (AFB) sputum staining or sputum culture [3].

The pathogenesis of TB is an interaction between *Mycobacterium tuberculosis* and the host [4]. The process begins with alveolar macrophages and dendritic cells as the first cells facing *Mycobacterium tuberculosis* bacteria. Macrophages' response as the mainline in dealing with *Mycobacterium tuberculosis* infection is influenced by various inflammatory mediators [5]. The failure of macrophages to control the number of *Mycobacterium tuberculosis* will result in the significant growth of

bacteria [6,7].

This condition emphasizes the important role of the host immune system in determining the susceptibility of TB to relapse. Several studies pointed out that Prostaglandin E₂ (PGE₂) affects macrophages as the main cells in the innate immune system. PGE₂ induces apoptosis and inhibits necrosis of macrophages infected with *Mycobacterium tuberculosis* [5,8,9]. Macrophage apoptosis is reported to reduce the growth rate of *Mycobacterium tuberculosis*, which is very important in the elimination mechanism of bacteria that infects the lungs, whereas necrosis plays the opposite role [5,8,10]. When the growth of *Mycobacterium tuberculosis* cannot be inhibited, the number of bacteria will increase. The high number of bacteria is reflected in the degree of phlegm AFB positivity. The higher the value of positivity for AFB in sputum, the greater the number of *Mycobacterium tuberculosis* bacteria contained in each ml of sputum [11]. The higher the number of bacteria, the easier it is to transmit, broader lung damage, and an increased risk of resistance [12, 13].

Based on the facts above, this study further revealed the association

* Corresponding author. Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Jl. Mayjend Prof. Dr. Moestopo No. 6-8, Airlangga, Gubeng, Surabaya, East Java 60286, Indonesia.

E-mail address: resti.yudhawati2021@gmail.com (R. Yudhawati).

<https://doi.org/10.1016/j.amsu.2021.103008>

Received 27 August 2021; Received in revised form 28 October 2021; Accepted 31 October 2021

Available online 3 November 2021

2049-0801/© 2021 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY license

(<http://creativecommons.org/licenses/by/4.0/>).

between PGE₂, which represents the innate immune system, and the degree of phlegm AFB positivity, which represents the number of bacteria. This research is important because no similar study was conducted in humans, so it is hoped that this research could provide further research.

2. Methods

2.1. Participants

Participants in this study were both new and relapsed patients with pulmonary tuberculosis. The inclusion criteria were patients diagnosed with pulmonary tuberculosis [3,14], positive sputum examination results for AFB, aged 21–65 years, who cooperated during the research procedure. Meanwhile, the exclusion criteria included patients with risk factors for immunocompromised (AIDS, malignancy, and systemic lupus erythematosus), patients having received anti-tuberculosis drug therapy for their current illness, patients taking non-steroidal anti-inflammatory drugs and/or corticosteroids in the past week.

2.2. Ethical clearance

Participants and their families filled out the consent form before the study. Participants filled out the consent form consciously and without coercion. This study received ethical approval based on the Declaration of Helsinki and obtained the registry of research at the Health Research Ethics Committee in the Hospital.

2.3. Study design

A cross-sectional study was carried out from August 2019–July 2020. The number of participants in this study was 62 patients that were obtained using Ronald Fisher's classic z transformation formula. The sample collection used a consecutive sampling technique (Fig. 1). Serum PGE₂ levels and levels of AFB in sputum were taken from the participants. This study report is by the Strengthening the Reporting of Cohort Studies in Surgery (STROCSS) 2019 guideline [15].

2.4. Measurement of serum PGE₂ level

Serum PGE₂ level is the total concentration of PGE₂ in the blood of pulmonary tuberculosis patients. This examination was carried out by taking 3–5 ml of the patient's venous blood and analyzed using the Elisa

Kit PGE₂ (pg/ml). Serum PGE₂ level is categorized into high if the value is more than 400 pg/ml, normal if the value is 200–400 pg/ml, and low if the value is less than 200 pg/ml [16].

2.5. Acid-fast bacilli test

Sputum examination was conducted to determine the degree of the participant's AFB positivity. Sputum collection for participants is carried out by the patient independently in the morning [17] which the participant gets an explanation from a pulmonary specialist regarding effective deep breathing and coughing techniques [18]. The sputum is put into a tube that has been prepared previously and then taken to the laboratory for analysis. The examination of AFB in the participant's sputum used the acid-fast staining method (Ziehl Nielsen) or the rapid molecular test of sputum with the GeneXpert machine [19]. The degree of phlegm AFB positivity was assessed based on the International Union Against Tuberculosis Lung Disease (IUATLD) standards which were categorized into 2: low (1+ and scanty) and high (2+ and 3+) [19,20].

2.6. Statistical analysis

The analysis in this study used descriptive analysis and bivariate analysis. Descriptive analysis included the presentation of the results descriptively using the distribution table, mean, median, standard deviation, maximum value, and minimum value. Meanwhile, bivariate analysis was used to assess the association between two variables. The association between variables was analyzed using the Chi-Square test and assessed the association strength using the Spearman correlation test. The analysis was declared significant if $p < 0.05$. The analysis was assisted by IBM SPSS Statistics software version 21.0 (IBM Corp., Armonk, NY, USA).

3. Results

3.1. Characteristic of participant

Most participants were male who was 43.37 ± 12.58 years old. Meanwhile, the median of participants' age was 44.5 years, with the lowest age being 21 years and the highest being 64 years. Some patients had a smoking habit (56.5%) and comorbidity of diabetes mellitus (32.3%). A total of 37 participants were new tuberculosis patients and the rest were relapsed, tuberculosis patients. Most participants had a body mass index (BMI) in the skinny category as much as 53.2%




Fig. 1. Participant requirement process.

Table 1
Characteristic of participant.

Variable	n (%)
Sex	
Male	36 (58.1)
Female	26 (41.9)
Education	
Elementary School	8 (12.9)
Junior High School	12 (19.4)
Senior High School	34 (54.8)
College	7 (11.3)
Not attending school	1 (1.6)
History of Diabetes Mellitus	
Yes	20 (32.3)
No	42 (67.7)
History of Tuberculosis Treatment	
New case	37 (59.7)
Relapse	25 (40.3)
Smoking Habit	
Smoking	35 (56.5)
No smoking	27 (43.5)
Degree of Acid-Fast Bacilli Positivity	
Low	26 (41.9)
High	36 (58.1)
Serum PGE ₂ Level	
Low	9 (14.5)
Normal	39 (62.9)
High	14 (22.6)
Body Mass Index	
Skinny (<18.5 kg/m ²)	33 (53.2)
Normal (18.5–25.0 kg/m ²)	24 (38.7)
Fat (>25.0 kg/m ²)	5 (8.1)

(Table 1). The average BMI value was 19.46 ± 4.05 kg/m², with a value range of 14.20–38.28 kg/m².

3.2. Distribution of serum PGE₂ levels in tuberculosis patients

Most participants had normal serum PGE₂ levels (62.9%; Table 1). The average participants had serum PGE₂ levels of 446.37 ± 510.27 pg/ml, with a median value of 216.95 pg/ml. The lowest and highest value of the participants' serum PGE₂ levels were 191.00 pg/ml and 2374.00 pg/ml, respectively. The serum PGE₂ levels of smoking and non-smoking participants was 228.80 (191.0–2,3374.0) pg/ml and 214.40 (198.3–1724.0) pg/ml, respectively. Most serum PGE₂ levels of smoking participants were normal (50%), while the serum PGE₂ levels of non-smoking participants were mostly normal (78%; $p = 0.053$). The median value of serum PGE₂ levels for participants with and without diabetes mellitus was 217.30 (191.0–1986.0) pg/ml and 216.80 (193.0–2374.0) pg/ml, respectively. The value of serum PGE₂ levels of participants with and without diabetes mellitus were 45% and 71%, respectively, indicating that most participants had normal values ($p =$

Table 2
Distribution of serum PGE₂ levels in tuberculosis patients.

Variable	Serum PGE ₂ Levels			p
	Low	Normal	High	
Pulmonary Tuberculosis				
New case	6 (16)	23 (62)	8 (22)	0.292
Relapse case	3 (12)	16 (64)	6 (24)	
Diabetes mellitus				
Yes	4 (20)	9 (45)	7 (35)	0.118
No	5 (12)	30 (71)	7 (17)	
BMI				
Skinny	1 (3)	24 (73)	8 (24)	0.058
Normal	7 (29)	12 (50)	5 (21)	
Fat	1 (20)	3 (60)	1 (20)	
Smoking				
Yes	6 (18)	17 (50)	11 (32)	0.053
No	3 (11)	22 (78)	3 (11)	

Abbreviation: BMI = body mass index.

0.118; Table 2).

Most of the participants' serum PGE₂ levels were normal in both groups of participants with a new diagnosis of pulmonary tuberculosis (62%) and relapsed (64%; $p = 0.292$). The median value of serum PGE₂ levels for participants diagnosed with new pulmonary tuberculosis was 215.70 (191.0–1724.0) pg/ml and participants diagnosed with relapsed pulmonary tuberculosis was 224.40 (193.2–2374.0) pg/ml. Participants' serum PGE₂ levels that were categorized by BMI were mostly normal, with 73% of skinny participants, 50% of normal participants, and 60% of fat participants ($p = 0.058$; Table 3). The median value of serum PGE₂ levels of participants with BMI in the skinny category was 222.60 (194.3–1986.0) pg/ml, normal was 210.30 (191.0–2374.0) pg/ml, and fat was 216.40 (199.0–1497.0) pg/ml.

3.3. Distribution of positivity of acid-fast bacilli in sputum of tuberculosis patients

Most participants had a high degree of AFB positivity in sputum as much as 58.1% (Table 1). Most participants who were diagnosed with new cases of pulmonary tuberculosis had a high degree of AFB positivity (68%). Meanwhile, most participants diagnosed with relapsed pulmonary tuberculosis had a low positivity degree (56%; $p = 0.065$). Some participants had a high degree of AFB positivity in participants with and without a history of diabetes mellitus of 65% and 55%, respectively ($p = 0.455$). Participants' BMI was categorized into 3, namely skinny, normal, and fat, in which some participants had a high degree of AFB positivity ($p = 0.561$). Most smoking (56%) and non-smoking (61%) participants had high positivity of AFB ($p = 0.798$; Table 3).

4. Association between serum PGE₂ levels and positivity of acid-fast bacilli in sputum of tuberculosis patients

The results showed that most participants with low (89%) and high (71%) serum PGE₂ levels had a high positivity of AFB in sputum as much as 89%. Meanwhile, participants with normal serum PGE₂ levels had a low positivity degree of AFB in sputum as much as 54% ($p = 0.036$). The strength of the association between serum PGE₂ levels and the degree of AFB positivity in sputum obtained $r = -0.036$ and p -value = 0.780 (Table 4).

5. Discussion

PGE₂ is a derivative of arachidonic acid produced by various inflammatory cells, especially macrophages. PGE₂, as an inflammatory mediator, plays a role in regulating various cell functions, namely macrophages, T cells, etc. In addition, PGE₂ plays a role in various body functions such as blood pressure regulation, temperature regulation, gastric protection, and childbirth [21]. Under various conditions such as

Table 3
Distribution of positivity of acid-fast bacilli in sputum of tuberculosis patients.

Variable	Degree of Acid-Fast Bacilli Positivity		p
	Low (%)	High	
Pulmonary Tuberculosis			
New case	12 (32)	25 (68)	0.065
Relapse case	14 (56)	11 (44)	
Diabetes Mellitus			
Yes	7 (35)	13 (65)	0.455
No	19 (45)	23 (55)	
BMI			
Skinny	15 (45)	18 (55)	0.561
Normal	10 (42)	14 (58)	
Fat	1 (20)	4 (80)	
Smoking			
Yes	15 (45)	19 (56)	0.798
No	11 (39)	17 (61)	

Abbreviation: BMI = body mass index.

Table 4

Association between PGE₂ levels and positivity of acid-fast bacilli in the sputum of tuberculosis patients.

Variable	Tuberculosis Positivity		<i>p</i> ^a	<i>r</i>	<i>p</i> ^b
	Low	High			
PGE ₂ Levels					
Low	1 (11)	8 (89)	0.036	-0.036	0.780
Normal	21 (54)	18 (46)			
High	4 (29)	10 (71)			

Note: *p*^a = Chi-square test; *p*^b = Spearman's correlation test.

changes in environmental temperature, hunger conditions, stress, PGE₂ will be produced so that levels in the body will rise and fall in various ways [22].

Schoenberger et al. reported an increase in serum PGE₂ levels in patients with diabetic retinopathy [23]. A study conducted by Lo et al. showed that the increase in serum PGE₂ levels was due to the upregulation of the cyclooxygenase-2 (COX₂) enzyme in patients with diabetes mellitus [24]. Kumar et al. reported differences in plasma PGE₂ levels in TB patients compared to TB-DM [16]. These results are inconsistent with various studies that reported increased levels of PGE₂ in smokers. Amadio et al. reported an increase in PGE₂ production in smokers due to the modulation of expression of tissue factors exposed to cigarette smoke [25]. Chen et al. in their study also reported the role of cigarette smoke in increasing PGE₂ production [26].

The condition obtained in this study seemed to occur because of the patient's experience factor. In patients with relapse cases, the experience of suffering from TB in the past will make the patient who has a cough immediately come to the health facility. Meanwhile, new case patients ignore the cough complaint that leads to accompanying complaints such as weight loss, hemoptysis, or fever. When these accompanying complaints occur, the course of TB disease would be long enough to increase the number of bacteria [1].

The profile of serum PGE₂ levels showed that the average participants had 446.23 pg/ml, with a standard deviation of 510.27 pg/ml. According to some literature, normal serum PGE₂ levels range from 200 to 400 pg/ml [16]. PGE₂ is a derivative of arachidonic acid produced mainly by inflammatory cells to face invading pathogens from outside. The effect of PGE₂ will trigger apoptosis of macrophages infected with *Mycobacterium tuberculosis* [4]. Macrophage apoptosis will have an elimination effect because *Mycobacterium tuberculosis* bacteria can be destroyed. PGE₂ also suppresses macrophage necrosis which can lead to bacterial dissemination. Increased levels of PGE₂ are associated with a decrease in the number of bacteria in the lung [7].

The negative association between serum PGE₂ levels and the degree of phlegm AFB positivity is by a study conducted by Dietzold and Amaral. Dietzold et al. reported that high levels of PGE₂ and low levels of LXA₄ suppress the growth of *Mycobacterium tuberculosis* [7]. Amaral et al. also reported that PGE₂ is associated with macrophage apoptosis in vitro. Apoptotic macrophages infected with *Mycobacterium tuberculosis* will increase the elimination of these bacteria [4]. The two studies above reported a significant association between PGE₂ and the growth of *Mycobacterium tuberculosis*. The statistical analysis results of this study showed that the association between serum PGE₂ levels and the degree of AFB positivity was not statistically significant. The main difference between this study and the two studies above is that both were carried out on mice and in vitro, whereas this study was conducted on pulmonary TB patients with various complications and uncontrollable comorbidities.

The results of this study can be used as consideration for conducting further research on the predictor factors for the positivity of AFB in pulmonary TB patients. The use of PGE₂ together with LXA₄ is expected to be able to assist clinicians in predicting the level of AFB positivity in pulmonary TB patients with specific chest X-ray images but difficulty in expectorating phlegm. In addition, in the future study it can be

considered to analyze the comparison of PGE₂ in TB patients, smokers patients, smokers with tuberculosis, etc.

Nevertheless, this study has several limitations. First, extreme serum PGE₂ levels were found in some research subjects. This can be caused by various factors that can increase PGE₂ levels that cannot be controlled. Second, this study only examined PGE₂ levels in TB patients without comparing them with PGE₂ levels in healthy persons, so it cannot be used as a predictor factor for the degree of positivity of AFB with sputum.

6. Conclusion

The average age of new and relapsed pulmonary TB patients is 43.37 years, mostly male, have a high school education, have a smoking habit, have a low BMI, and have no history of DM. The median serum PGE₂ level of new and relapsed pulmonary TB patients was 216.95 pg/ml. The majority of new pulmonary TB patients have a high degree of positivity for AFB in sputum, but relapsed pulmonary TB patients have a low degree of positivity for AFB. This study finds a weak negative association between serum PGE₂ levels and the degree of phlegm AFB positivity but not statistically significant.

Please state any sources of funding for your research

None.

Ethical approval

We have conducted an ethical approval base on Declaration of Helsinki at Ethical Committee in Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.

Consent

Written informed consent was obtained from the patient.

Author contribution

All authors contributed toward data analysis, drafting and revising the paper, gave final approval of the version to be published and agree to be accountable for all aspects of the work.

Registration of research studies

1. Name of the registry: Health Research Ethics Committee in the Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
2. Unique Identifying number or registration ID: 1355/KEKP/VII/2019.
3. Hyperlink to your specific registration (must be publicly accessible and will be checked):-.

Guarantor

Resti Yudhawati.

Funding

Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Declaration of competing interest

The authors declare that they have no conflict of interest.

Acknowledgment

We would like to thank the Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia for providing support for our study. We would like to thank Fis Citra Ariyanto as our manuscript editor.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.amsu.2021.103008>.

References

- [1] WHO Guidelines Approved by the Guidelines Review Committee. WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment - Drug-Resistant Tuberculosis Treatment, World Health Organization, Geneva, 2020.
- [2] E. Harding, WHO global progress report on tuberculosis elimination, *The Lancet Respiratory medicine* 8 (1) (2020) 19, [https://doi.org/10.1016/s2213-2600\(19\)30418-7](https://doi.org/10.1016/s2213-2600(19)30418-7).
- [3] M. Erawati, M. Andriany, The prevalence and demographic risk factors for latent tuberculosis infection (LTBI) among healthcare workers in Semarang, Indonesia, *J. Multidiscip. Healthc.* 13 (2020) 197–206, <https://doi.org/10.2147/jmdh.S241972>.
- [4] E.P. Amaral, E.B. Lasunskaia, M.R. D'Império-Lima, Innate immunity in tuberculosis: how the sensing of mycobacteria and tissue damage modulates macrophage death, *Microb. Infect.* 18 (1) (2016) 11–20, <https://doi.org/10.1016/j.micinf.2015.09.005>.
- [5] M. Mirsaeidi, R.T. Sadikot, Patients at high risk of tuberculosis recurrence, *International journal of mycobacteriology* 7 (1) (2018) 1–6, <https://doi.org/10.4103/ijmy.ijmy.164.17>.
- [6] J. Lee, M. Hartman, H. Kornfeld, Macrophage apoptosis in tuberculosis, *Yonsei Med. J.* 50 (1) (2009) 1–11, <https://doi.org/10.3349/ymj.2009.50.1.1>.
- [7] J. Dietzold, A. Gopalakrishnan, P. Salgame, Duality of lipid mediators in host response against *Mycobacterium tuberculosis*: good cop, bad cop, *F1000prime reports* 7 (2015) 29, <https://doi.org/10.12703/p7-29>.
- [8] S.M. Behar, C.J. Martin, M.G. Booty, T. Nishimura, X. Zhao, H.X. Gan, et al., Apoptosis is an innate defense function of macrophages against *Mycobacterium tuberculosis*. *Mucosal immunology* 4 (3) (2011) 279–287, <https://doi.org/10.1038/mi.2011.3>.
- [9] A. Ambreen, M. Jamil, M.A.U. Rahman, T. Mustafa, Viable *Mycobacterium tuberculosis* in sputum after pulmonary tuberculosis cure, *BMC Infect. Dis.* 19 (1) (2019) 923, <https://doi.org/10.1186/s12879-019-4561-7>.
- [10] A. Lam, R. Prabhu, C.M. Gross, L.A. Riesenber, V. Singh, S. Aggarwal, Role of apoptosis and autophagy in tuberculosis, *Am. J. Physiol. Lung Cell Mol. Physiol.* 313 (2) (2017), <https://doi.org/10.1152/ajplung.00162.2017>. L218-129.
- [11] H. Kaur, N. Chand, B. Malhotra, S.P. Singh, V. Verma, S. Thakur, et al., Sputum grading as predictor of treatment outcome in pulmonary tuberculosis, *Chest* 132 (2007) 475A, https://doi.org/10.1378/chest.132.4_MeetingAbstracts.475a, 4, Supplement).
- [12] E. Hernández-Garduño, V. Cook, D. Kunitomo, R.K. Elwood, W.A. Black, J. M. FitzGerald, Transmission of tuberculosis from smear negative patients: a molecular epidemiology study, *Thorax* 59 (4) (2004) 286–290, <https://doi.org/10.1136/thx.2003.011759>.
- [13] S. Ravimohan, H. Kornfeld, D. Weissman, G.P. Bisson, Tuberculosis and lung damage: from epidemiology to pathophysiology, *Eur. Respir. Rev. : an official journal of the European Respiratory Society* 27 (147) (2018), <https://doi.org/10.1183/16000617.0077-2017>.
- [14] N.M. Mertaniasih, D. Kusumaningrum, E.B. Koendhori, T. Kusmiati, D.N. Dewi, Nontuberculous mycobacterial species and *Mycobacterium tuberculosis* complex coinfection in patients with pulmonary tuberculosis in Dr. Soetomo Hospital, Surabaya, Indonesia, *International journal of mycobacteriology* 6 (1) (2017) 9–13, <https://doi.org/10.4103/2212-5531.201894>.
- [15] R. Agha, A. Abdall-Razak, E. Crossley, N. Dowlut, C. Iosifidis, G. Mathew, STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery, *Int. J. Surg.* 72 (2019) 156–165, <https://doi.org/10.1016/j.ijsu.2019.11.002>.
- [16] N.P. Kumar, K. Moideen, A. Nancy, V. Viswanathan, B.S. Shruithi, S. Shanmugam, et al., Plasma eicosanoid levels in tuberculosis and tuberculosis-diabetes Comorbidity are associated with lung pathology and bacterial burden, *Frontiers in cellular and infection microbiology* 9 (2019) 335, <https://doi.org/10.3389/fcimb.2019.00335>.
- [17] M.E. Murphy, P.P.J. Phillips, C.M. Mendel, E. Bongard, A.L.C. Bateson, R. Hunt, et al., Spot sputum samples are at least as good as early morning samples for identifying *Mycobacterium tuberculosis*, *BMC Med.* 15 (1) (2017) 192, <https://doi.org/10.1186/s12916-017-0947-9>.
- [18] S. Ren, W. Li, L. Wang, Y. Shi, M. Cai, L. Hao, et al., Numerical analysis of airway mucus clearance effectiveness using assisted coughing techniques, *Sci. Rep.* 10 (1) (2020) 2030, <https://doi.org/10.1038/s41598-020-58922-7>.
- [19] P.M. Christopher, A. Widysanto, GeneXpert *Mycobacterium tuberculosis*/rifampicin assay for molecular epidemiology of rifampicin-Resistant *Mycobacterium tuberculosis* in an Urban Setting of Banten province, Indonesia, *International journal of mycobacteriology* 8 (4) (2019) 351–358, <https://doi.org/10.4103/ijmy.ijmy.138.19>.
- [20] M.A. Aziz, A. Wright, The world health organization/international union against tuberculosis and lung disease global project on surveillance for anti-tuberculosis drug resistance: a model for other infectious diseases, *Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America* 41 (Suppl 4) (2005) S258–S262, <https://doi.org/10.1086/430786>.
- [21] E. Ricciotti, G.A. FitzGerald, Prostaglandins and inflammation, *Arterioscler. Thromb. Vasc. Biol.* 31 (5) (2011) 986–1000, <https://doi.org/10.1161/atvbaha.110.207449>.
- [22] E.M. Poole, L. Hsu, L. Xiao, R.J. Kulmacz, C.S. Carlson, P.S. Rabinovitch, et al., Genetic Variation in Prostaglandin E2 Synthesis and Signaling, Prostaglandin Dehydrogenase, and the Risk of Colorectal Adenoma. *Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research*, cosponsored by the American Society of Preventive Oncology, 2010, pp. 547–557, <https://doi.org/10.1158/1055-9965.Epi-09-0869>, 19(2).
- [23] S.D. Schoenberger, S.J. Kim, J. Sheng, K.A. Rezaei, M. Lalezary, E. Cherney, Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines, *Investig. Ophthalmol. Vis. Sci.* 53 (9) (2012) 5906–5911, <https://doi.org/10.1167/iovs.12-10410>.
- [24] C.J. Lo, Upregulation of cyclooxygenase-II gene and PGE2 production of peritoneal macrophages in diabetic rats, *J. Surg. Res.* 125 (2) (2005) 121–127, <https://doi.org/10.1016/j.jss.2004.12.005>.
- [25] P. Amadio, D. Baldassarre, E. Tarantino, E. Zacchi, S. Gianellini, I. Squellerio, et al., Production of prostaglandin E2 induced by cigarette smoke modulates tissue factor expression and activity in endothelial cells, *Faseb. J. : official publication of the Federation of American Societies for Experimental Biology* 29 (9) (2015) 4001–4010, <https://doi.org/10.1096/fj.14-268383>.
- [26] Y.-J. Chen, S.-S. Lee, F.-M. Huang, Y.-C. Chang, Effects of nicotine on differentiation, prostaglandin E2, and nitric oxide production in cementoblasts, *J. Dent. Sci.* 10 (4) (2015) 431–436, <https://doi.org/10.1016/j.jds.2015.03.007>.